Stereotactic body radiation therapy for liver oligo-recurrence and oligo-progression from various tumors
Radiation Oncology Journal
;
: 172-179, 2017.
Article
in English
| WPRIM
| ID: wpr-44435
ABSTRACT
PURPOSE:
To evaluate the outcomes of stereotactic body radiation therapy (SBRT) for patients with liver oligo-recurrence and oligo-progression from various primary tumors. MATERIALS ANDMETHODS:
Between 2002 and 2013, 72 patients with liver oligo-recurrence (oligo-metastasis with a controlled primary tumor) and oligo-progression (contradictory progression of a few sites of disease despite an overall tumor burden response to therapy) underwent SBRT. Of these, 9 and 8 patients with uncontrollable distant metastases and patients immediate loss to follow-up, respectively, were excluded. The total planning target volume was used to select the SBRT dose (median, 48 Gy; range, 30 to 60 Gy, 3–4 fractions). Toxicity was evaluated using the Common Toxicity Criteria for Adverse Events v4.0.RESULTS:
We evaluated 55 patients (77 lesions) treated with SBRT for liver metastases. All patients had controlled primary lesions, and 28 patients had stable lesions at another site (oligo-progression). The most common primary site was the colon (36 patients), followed by the stomach (6 patients) and other sites (13 patients). The 2-year local control and progression-free survival rates were 68% and 22%, respectively. The 2- and 5-year overall survival rates were 56% and 20%, respectively. The most common adverse events were grade 1–2 fatigue, nausea, and vomiting; no grade ≥3 toxicities were observed. Univariate analysis revealed that oligo-progression associated with poor survival.CONCLUSION:
SBRT for liver oligo-recurrence and oligo-progression appears safe, with similar local control rates. For liver oligo-progression, criteria are needed to select patients in whom improved overall survival can be expected through SBRT.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Stomach
/
Vomiting
/
Survival Rate
/
Follow-Up Studies
/
Colon
/
Disease-Free Survival
/
Tumor Burden
/
Fatigue
/
Liver
/
Nausea
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Radiation Oncology Journal
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS